IN8bio logo

IN8bio

INAB | NASDAQ
Chart Builder DCF Calculator
$0.77
-$0.05 (-6.10%)
At close: Nov 16, 2026, 3:59 PM ET
$0.80
+$0.03 (+3.86%)
After-hours: Nov 16, 2026, 7:52 PM ET
-6.10%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
34.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #667/1021 (Top 65%)

Key Statistics

Market Data

Market Cap $14.99M
1D Range
0.72 1.02
52W Range
0.72 2.59

Valuation (TTM)

PE -0.61
PB 1.06
EV/EBITDA -0.21

Valuation (NTM)

Forward PE N/A
Forward PEG 0.01
Price Target $4.00
Loading financial charts...

Profile

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various for...

Sector Healthcare
Industry Biotechnology
Employees 18
IPO Date Jul 30, 2021
Website in8bio.com
Fiscal Year January - December

Latest News

No news articles available yet.

Analyst Summary

# of Analysts
1
Consensus
Buy
Price Target
$4.00
Upside
+419.48%
Buy (1)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.